<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02334267</url>
  </required_header>
  <id_info>
    <org_study_id>ABChD</org_study_id>
    <nct_id>NCT02334267</nct_id>
  </id_info>
  <brief_title>Acid-Base Composition With Use of hemoDialysates</brief_title>
  <acronym>ABChD</acronym>
  <official_title>Acid-Base Composition With Use of hemoDialysates: the ABChD Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care North America</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care North America</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, single center, single blind (patient and laboratory),
      randomized, cross-over, two week investigation of intradialytic acid-base kinetics and
      physiology associated with use of two commercial acid dialysate concentrates in prevalent
      hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 10-20 prevalent hemodialysis patients will be recruited. Subjects will
      randomized to receive one weekly hemodialysis treatment using each of the two acetate acid
      dialysate buffers of NaturaLyte and GranuFlo, which will be assigned in a random fashion.
      Acetate and bicarbonate concentrations will be assessed before, at eight time points during,
      and six time points after the completion of hemodialysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peridialytic Arterialized Blood Bicarbonate Concentrations</measure>
    <time_frame>Immediately prior to initiation of hemodialysis, and 25, 60, 90, 120, 150, 180, 210, 240 minutes of hemodialysis and 15, 30, 45, 60, 75, and 90 minutes post hemodialysis</time_frame>
    <description>Quantification of Peridialytic Arterialized Blood Bicarbonate Concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peridialytic Venous Blood Bicarbonate Concentrations</measure>
    <time_frame>25, 60, 90, 120, 150, 180, 210, 240 minutes of hemodialysis</time_frame>
    <description>Quantification of Peridialytic Venous Blood Bicarbonate Concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peridialytic Arterialized Blood Acetate Concentrations</measure>
    <time_frame>Immediately prior to initiation of hemodialysis, and 25, 60, 90, 120, 150, 180, 210, 240 minutes of hemodialysis and 15, 30, 45, 60, 75, and 90 minutes post hemodialysis</time_frame>
    <description>Quantification of Peridialytic Arterialized Blood Acetate Concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peridialytic Venous Blood Acetate Concentrations</measure>
    <time_frame>25, 60, 90, 120, 150, 180, 210, 240 minutes of hemodialysis</time_frame>
    <description>Quantification of Peridialytic Venous Blood Acetate Concentrations</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Group 1: GranuFlo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of NaturaLyte for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: NaturaLyte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of GranuFlo for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Group 1: GranuFlo</intervention_name>
    <description>Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.</description>
    <arm_group_label>Group 1: GranuFlo</arm_group_label>
    <other_name>GranuFlo 45X</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Group 2: NaturaLyte</intervention_name>
    <description>Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.</description>
    <arm_group_label>Group 2: NaturaLyte</arm_group_label>
    <other_name>NaturaLyte 45X</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects eligible to be entered into this study will meet all of the following criteria:

          1. Adult female or male patients; age ≥18 years.

          2. End stage renal disease (ESRD) patients treated for &gt;90 days with the modality of
             maintenance hemodialysis and on a stable dialysis prescription for the prior month.

          3. Patients utilizing a hemodialysis vascular access of a functioning arteriovenous
             fistula (AVF) or graft (AVG) during the prior month. The patient's AVF/AVG must be
             considered in stable functioning condition and not be expected to require any surgical
             revision/intervention during participation in the trial.

          4. Patients with an average spKt/V of ≥1.2 during 30 days prior to screening as
             determined by historic monthly laboratory adequacy measurements; for patients with
             only one available spKt/V an average will not be performed. (Note: spKt/V should not
             be captured from dialysis machine adequacy measurements.)

          5. Screening hemoglobin level of ≥9 g/dL, and investigator considers hemoglobin levels to
             have been clinically stable for at least 30 days.

          6. A sodium bicarbonate basic dialysate prescription that has not had any changes for 30
             days prior to randomization, and is anticipated to be unchanged during study
             participation as determined by the investigator.

          7. Unchanged heparin dosing regimen for the past 30 days prior to randomization and
             anticipated unchanged heparin dosing during participation in this clinical trial.

          8. No changes two weeks prior to randomization or anticipated changes throughout the
             study in any phosphate binders, calcium supplements, anticoagulant therapies that are
             not used for hemodialysis treatment (e.g. warfarin, dabigatran, apixaban, rivaroxaban
             and acetylsalicylic acid (ASA)), non-dialysate sodium bicarbonate and/or citrate based
             concomitant medications.

          9. If treated with systemic glucocorticoid/corticosteroid medications, no dose changes in
             the previous two months before randomization, or anticipated dose changes throughout
             the study duration; the dosing regimen should be consistent with maintenance therapy
             (i.e. not for an acute or active uncontrolled disease) as determined by the
             investigator. (Note: this criteria does not pertain to inhaled and/or topical
             glucocorticoid/corticosteroid therapies)

         10. During the two weeks prior to screening, an average of no more than 3.5 kg in
             pre-dialysis weight gain. In the event greater than 3.5 kg is noted, the investigator
             will discuss the specific medical history with the Medical Monitor prior to
             enrollment.

         11. Willing to comply with all study procedures and be available for the duration of the
             study.

        Exclusion Criteria:

        Patients that meet any of the following criteria will be ineligible for this study:

          1. Patients unable to provide a signed and dated informed consent for this clinical
             research study.

          2. Pregnant or lactating female patients.

          3. Females of reproductive potential who do not agree to use a highly effective method of
             contraception, as determined by the investigator.

          4. Missed a scheduled outpatient dialysis treatment within two weeks prior to screening
             or anticipated to not attend any prescribed hemodialysis treatments during
             participation in the study.

          5. Screening or historic laboratory values of aspartate aminotransferase (AST), alanine
             transaminase (ALT), and alkaline phosphatase (ALP) levels ≥ 2 times the upper limit of
             normal. These blood laboratory tests must have been performed within 30 days prior to
             screening or prior to randomization.

          6. A screening or historic laboratory value of total bilirubin &gt;1.9 mg/dL that was
             collected within 30 days prior to screening or obtained before randomization.

          7. Uncontrolled clinically significant blood pressure as determined by the investigator
             within 30 days prior to screening.

          8. Active or recent bleeding disorder within the past 30 days.

          9. Screening or historic platelet count &lt;100,000 platelets per microliter (mcL) that was
             collected within 30 days prior to screening or before randomization.

         10. Chronic supplemental oxygen use within 30 days prior to randomization.

         11. Current active and significant chronic obstructive pulmonary disease (COPD) as
             determined by the investigator.

         12. Significant residual renal function as determined by the investigator. If the amount
             of residual renal function is in doubt, a 24 hour urine will be collected during the
             clinic admission to confirm the creatinine clearance. Decisions will be made after the
             results have been obtained as to the inclusion of data for these subjects.

         13. Active malignancy or a malignancy within the past five years, with exceptions for
             basal and squamous cell carcinoma.

         14. Active and clinically uncontrolled autoimmune disease as determined by the
             investigator. Subjects with controlled autoimmune diseases must be considered to be
             clinically stable in the opinion of the investigator (e.g. subjects with systemic
             lupus erythematosus (SLE) and no recent flares are not excluded). The investigator
             will consult with the referring physician if it is necessary to confirm the stability
             of an autoimmune disease.

         15. Diagnosed with human immunodeficiency virus (HIV).

         16. Diagnosed with congestive heart failure (CHF) class III or IV as classified by the New
             York Heart Association (NYHA) (refer to Appendix A) within the past 60 days.

         17. Planned or anticipated need for any surgical procedures during participation in the
             study.

         18. Current or recent illicit drug use or alcohol abuse as determined by the investigator.

         19. Subjects that have any significant medical condition as determined by the
             investigator, which make her/him ineligible for the study (e.g. clinically significant
             vomiting on dialysis which affects acid-base status).

         20. Any condition as determined by the investigator that would place the subject at an
             increased risk, or preclude the subject's full compliance with the study procedures
             and visits.

         21. Treatment with an investigational drug, device or intervention within 30 days prior to
             and during participation in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William B Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Volunteer Research Group and New Orleans Center for Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Volunteer Research Group and New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2015</study_first_posted>
  <results_first_submitted>February 10, 2016</results_first_submitted>
  <results_first_submitted_qc>January 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2017</results_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
    <mesh_term>Hemodialysis Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 Week 1 GranuFlo and Week 2 NaturaLyte</title>
          <description>Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of NaturaLyte for a second weekly hemodialysis treatment. Intervention: serum and dialysate samples will be obtained at specific timepoints during the dialysis treatments.
GranuFlow: Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: serum and dialysate samples will be obtained at specific timepoints during the dialysis treatments.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 Week 1 NaturaLyte and Week 2 GranuFlo</title>
          <description>Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of GranuFlo for a second weekly hemodialysis treatment. Intervention: serum and dialysate samples will be obtained at specific timepoints during the dialysis treatments.
NaturaLyte: Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: serum and dialysate samples will be obtained at specific timepoints during the dialysis treatments.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1Week 1 GranuFlo and Week 2 NaturaLyte</title>
          <description>Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of NaturaLyte for a second weekly hemodialysis treatment. Intervention: serum and dialysate samples will be obtained at specific timepoints during the dialysis treatments.
GranuFlow: Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: serum and dialysate samples will be obtained at specific timepoints during the dialysis treatments.</description>
        </group>
        <group group_id="B2">
          <title>Group 2 Week 1 NaturaLyte and Week 2 GranuFlo</title>
          <description>Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of GranuFlo for a second weekly hemodialysis treatment. Intervention: serum and dialysate samples will be obtained at specific timepoints during the dialysis treatments.
NaturaLyte: Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: serum and dialysate samples will be obtained at specific timepoints during the dialysis treatments.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peridialytic Arterialized Blood Bicarbonate Concentrations</title>
        <description>Quantification of Peridialytic Arterialized Blood Bicarbonate Concentrations</description>
        <time_frame>Immediately prior to initiation of hemodialysis, and 25, 60, 90, 120, 150, 180, 210, 240 minutes of hemodialysis and 15, 30, 45, 60, 75, and 90 minutes post hemodialysis</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>GranuFlo</title>
            <description>The outcome measure was peridialytic arterialized blood bicarbonate concentrations over time in subjects who received a hemodialysis treatment with a hemodialysate solution that was made from the acid dialysate concentrate GranuFlo</description>
          </group>
          <group group_id="O2">
            <title>NaturaLyte</title>
            <description>The outcome measure was peridialytic arterialized blood bicarbonate concentrations over time in subjects who received a hemodialysis treatment with a hemodialysate solution that was made from the acid dialysate concentrate NaturaLyte</description>
          </group>
        </group_list>
        <measure>
          <title>Peridialytic Arterialized Blood Bicarbonate Concentrations</title>
          <description>Quantification of Peridialytic Arterialized Blood Bicarbonate Concentrations</description>
          <population>Per Protocol Population</population>
          <units>mEq/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="3.33"/>
                    <measurement group_id="O2" value="27.1" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" spread="3.16"/>
                    <measurement group_id="O2" value="27.4" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="3.48"/>
                    <measurement group_id="O2" value="28.4" spread="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="3.85"/>
                    <measurement group_id="O2" value="28.6" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" spread="3.89"/>
                    <measurement group_id="O2" value="28.3" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>150 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="3.77"/>
                    <measurement group_id="O2" value="28.3" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="4.09"/>
                    <measurement group_id="O2" value="28.3" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>210 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="3.90"/>
                    <measurement group_id="O2" value="29.1" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="4.16"/>
                    <measurement group_id="O2" value="28.8" spread="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8" spread="4.34"/>
                    <measurement group_id="O2" value="29.9" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" spread="4.28"/>
                    <measurement group_id="O2" value="29.8" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 min post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" spread="3.91"/>
                    <measurement group_id="O2" value="29.8" spread="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 min post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" spread="3.64"/>
                    <measurement group_id="O2" value="30.5" spread="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75 min post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="4.10"/>
                    <measurement group_id="O2" value="29.6" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 min post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" spread="4.44"/>
                    <measurement group_id="O2" value="29.8" spread="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>trend analysis over time</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peridialytic Venous Blood Bicarbonate Concentrations</title>
        <description>Quantification of Peridialytic Venous Blood Bicarbonate Concentrations</description>
        <time_frame>25, 60, 90, 120, 150, 180, 210, 240 minutes of hemodialysis</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>GranuFlo</title>
            <description>The outcome measure was peridialytic venous blood bicarbonate concentrations over time in subjects who received a hemodialysis treatment with a hemodialysate solution that was made from the acid dialysate concentrate GranuFlo</description>
          </group>
          <group group_id="O2">
            <title>NaturaLyte</title>
            <description>The outcome measure was peridialytic venous blood bicarbonate concentrations over time in subjects who received a hemodialysis treatment with a hemodialysate solution that was made from the acid dialysate concentrate NaturaLyte</description>
          </group>
        </group_list>
        <measure>
          <title>Peridialytic Venous Blood Bicarbonate Concentrations</title>
          <description>Quantification of Peridialytic Venous Blood Bicarbonate Concentrations</description>
          <population>Per Protocol Population</population>
          <units>mEq/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>25 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="3.13"/>
                    <measurement group_id="O2" value="30.8" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" spread="3.83"/>
                    <measurement group_id="O2" value="30.7" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="3.36"/>
                    <measurement group_id="O2" value="31.2" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" spread="3.30"/>
                    <measurement group_id="O2" value="30.6" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>150 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8" spread="3.58"/>
                    <measurement group_id="O2" value="30.4" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" spread="3.83"/>
                    <measurement group_id="O2" value="31.3" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>210 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="3.94"/>
                    <measurement group_id="O2" value="31.0" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6" spread="3.92"/>
                    <measurement group_id="O2" value="30.9" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4</p_value>
            <p_value_desc>trend analysis over time</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peridialytic Arterialized Blood Acetate Concentrations</title>
        <description>Quantification of Peridialytic Arterialized Blood Acetate Concentrations</description>
        <time_frame>Immediately prior to initiation of hemodialysis, and 25, 60, 90, 120, 150, 180, 210, 240 minutes of hemodialysis and 15, 30, 45, 60, 75, and 90 minutes post hemodialysis</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>GranuFlo</title>
            <description>The outcome measure was peridialytic arterialized blood acetate concentrations over time in subjects who received a hemodialysis treatment with a hemodialysate solution that was made from the acid dialysate concentrate GranuFlo</description>
          </group>
          <group group_id="O2">
            <title>NaturaLyte</title>
            <description>The outcome measure was peridialytic arterialized blood acetate concentrations over time in subjects who received a hemodialysis treatment with a hemodialysate solution that was made from the acid dialysate concentrate NaturaLyte</description>
          </group>
        </group_list>
        <measure>
          <title>Peridialytic Arterialized Blood Acetate Concentrations</title>
          <description>Quantification of Peridialytic Arterialized Blood Acetate Concentrations</description>
          <population>Per Protocol Population</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.35"/>
                    <measurement group_id="O2" value="0.4" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.29"/>
                    <measurement group_id="O2" value="0.4" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.22"/>
                    <measurement group_id="O2" value="0.2" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.57"/>
                    <measurement group_id="O2" value="0.1" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.18"/>
                    <measurement group_id="O2" value="0.1" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>150 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.18"/>
                    <measurement group_id="O2" value="0.1" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.20"/>
                    <measurement group_id="O2" value="0.1" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>210 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.21"/>
                    <measurement group_id="O2" value="0.2" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.58"/>
                    <measurement group_id="O2" value="0.2" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.05"/>
                    <measurement group_id="O2" value="0.1" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.28"/>
                    <measurement group_id="O2" value="0.1" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 min post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.35"/>
                    <measurement group_id="O2" value="0.1" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 min post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.05"/>
                    <measurement group_id="O2" value="0.2" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75 min post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.61"/>
                    <measurement group_id="O2" value="0.6" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 min post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.61"/>
                    <measurement group_id="O2" value="0.4" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>trend analysis over time</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peridialytic Venous Blood Acetate Concentrations</title>
        <description>Quantification of Peridialytic Venous Blood Acetate Concentrations</description>
        <time_frame>25, 60, 90, 120, 150, 180, 210, 240 minutes of hemodialysis</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>GranuFlo</title>
            <description>The outcome measure was peridialytic venous blood acetate concentrations over time in subjects who received a hemodialysis treatment with a hemodialysate solution that was made from the acid dialysate concentrate GranuFlo</description>
          </group>
          <group group_id="O2">
            <title>NaturaLyte</title>
            <description>The outcome measure was peridialytic venous blood acetate concentrations over time in subjects who received a hemodialysis treatment with a hemodialysate solution that was made from the acid dialysate concentrate NaturaLyte</description>
          </group>
        </group_list>
        <measure>
          <title>Peridialytic Venous Blood Acetate Concentrations</title>
          <description>Quantification of Peridialytic Venous Blood Acetate Concentrations</description>
          <population>Per Protocol Population</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>25 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.62"/>
                    <measurement group_id="O2" value="1.0" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.60"/>
                    <measurement group_id="O2" value="1.0" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.81"/>
                    <measurement group_id="O2" value="0.9" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.74"/>
                    <measurement group_id="O2" value="1.0" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>150 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.67"/>
                    <measurement group_id="O2" value="1.1" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.70"/>
                    <measurement group_id="O2" value="1.1" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>210 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.83"/>
                    <measurement group_id="O2" value="1.1" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240 min of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.90"/>
                    <measurement group_id="O2" value="1.2" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>trend analysis over time</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GranuFlo</title>
          <description>The safety reporting group included subjects who received one study related hemodialysis treatment with a hemodialysate solution that was made from the acid dialysate concentrate GranuFlo.</description>
        </group>
        <group group_id="E2">
          <title>NaturaLyte</title>
          <description>The safety reporting group included subjects who received one study related hemodialysis treatment with a hemodialysate solution that was made from the acid dialysate concentrate NaturaLyte.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brigid Flanagan, MS, RN, CCRC</name_or_title>
      <organization>Frenova Renal Research</organization>
      <phone>781-699-2970</phone>
      <email>Brigid.Flanagan@frenovarenalresearch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

